Back to Search
Start Over
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
- Source :
- Expert Review of Pharmacoeconomics & Outcomes Research; Feb2020, Vol. 20 Issue 1, p133-138, 6p
- Publication Year :
- 2020
-
Abstract
- Purpose: This study aimed to investigate the cost-effectiveness of adjuvant treatments in resected pancreatic cancer.Methods: A Markov model was developed to mimic the disease process of postoperative pancreatic cancer, encompassing three health states (relapse-free survival, recurrent disease, and death). Health outcomes and utility scores were derived from the phase III trial and available literature. Cost data were calculated using standard fee data from the West China Hospital for 2017. One-way sensitivity analyses and probabilistic sensitivity analyses were developed to explore model uncertainty.Results: Treatment with S-1 was estimated to yield 1.61 quality-adjusted life-years (QALYs) at a cost of $25,696, whereas treatment with gemcitabine yielded 1.27 QALYs at a cost of $28,930. The incremental cost-effectiveness ratio of S-1 versus gemcitabine was $-9,490 per QALY. Based on the willingness-to-pay threshold of $25,841 per QALY, the net monetary benefit (NMB) was $15,786 for S-1 and $3,727 for gemcitabine, generating the incremental NMB of $12,059. A probabilistic sensitivity analysis revealed that the probabilities of S-1 and gemcitabine being cost-effective were 92% and 8%, respectively. Results were robust to changes in parameters.Conclusion: Adjuvant therapy using S-1 is a cost-effective alternative compared to gemcitabine in patients with postoperative pancreatic cancer from the Chinese societal perspective. [ABSTRACT FROM AUTHOR]
- Subjects :
- PANCREATIC tumors
RESEARCH
COMBINATION drug therapy
CLINICAL trials
HETEROCYCLIC compounds
RESEARCH methodology
ANTINEOPLASTIC agents
DEOXYCYTIDINE
CANCER relapse
PROGNOSIS
EVALUATION research
MEDICAL cooperation
ANTIMETABOLITES
FLUOROURACIL
COMPARATIVE studies
RANDOMIZED controlled trials
COST effectiveness
COMBINED modality therapy
QUALITY-adjusted life years
Subjects
Details
- Language :
- English
- ISSN :
- 14737167
- Volume :
- 20
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Expert Review of Pharmacoeconomics & Outcomes Research
- Publication Type :
- Academic Journal
- Accession number :
- 142800851
- Full Text :
- https://doi.org/10.1080/14737167.2020.1677155